The human DLC-1 (deleted in liver cancer 1) gene was cloned from a primary human hepatocellular carcinoma (HCC) and mapped to the chromosome 8p21-22 region frequently deleted in common human cancers and suspected to harbor tumor suppressor genes. DLC-1 was found to be deleted or downregulated in a significant number of HCCs. We expanded our investigations to other cancers with recurrent deletions of 8p22, and in this study examined alterations of DLC-1 in primary human breast tumors, human breast, colon, and prostate tumor cell lines. Genomic deletion of DLC-1 was observed in 40% of primary breast tumors, whereas reduced or undetectable levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines To see whether DLC-1 expression affects cell growth and tumorigenicity, two breast carcinoma cell lines lacking the expression of endogenous gene were transfected with the DLC-1 cDNA. In both cell lines, DLC-1 transfection caused significant growth inhibition and reduction of colony formation. Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.
Introduction
The human DLC-1 (deleted in liver cancer 1) gene was isolated from a primary human hepatocellular carcinoma (HCC) by representational difference analysis (Yuan et al., 1998) . Determination of the DLC-1 cDNA sequence showed that it is the human homologue of rat p122, which has been found to act as a GAP for RhoA, and to stimulate the hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C-d1 (Homma and Emori, 1995) . Both the DLC-1 and p122 sequences have a Rho GAP domain (Homma and Emori, 1995) and at least two other potential functional motifs, a sterile alpha motif domain and a StARrelated lipid-transfer domain (Ponting and Aravind, 1999) . Overexpression of p122 in cultured cells resulted in the loss of actin stress fibers and the detachment of cells from the substratum, implicating DLC-1/p122 in the signal transduction pathways that regulate cell morphology and adhesion (Sekimata et al., 1999) .
The DLC-1 gene was localized on chromosome 8p21-22, a region of loss of heterozygosity (LOH) in a number of human cancers such as prostate, colon, breast, ovarian, liver, lung, bladder, and head and neck cancer (reviewed in Arbieva et al., 2000; Xu et al., 2001) . Similarly, DNA copy-number losses in this region were identified by comparative genomic hybridization (CGH) in tumors of the breast, liver, colon, lung, ovary, bladder and prostate, as well as in osteosarcomas, mesotheliomas, B-cell lymphomas and mantle cell lymphoma (Martinez-Climent et al., 2001; Zitzelsberger et al., 1997) . Chromosome 8 transfer into colon and prostate tumor cell lines provided functional evidence for the presence of tumor suppressor genes on chromosome 8p21-22 (Gustafson et al., 1996; Cabeza-Arvelaiz et al., 2001) .
Deletion of the DLC-1 gene was found in human primary liver tumors and in HCC-derived cell lines (Yuan et al., 1998; Ng et al., 2000) . In normal adult tissues the DLC-1 gene is widely expressed, but in primary HCC and HCC cell lines its expression is either reduced or absent (Yuan et al., 1998; Ng et al., 2000) . Genomic deletion or promoter hypermethylation are responsible for aberrant expression of DLC-1 in HCC, as well as in breast, colon, and prostate cancer cells, while mutations are rather infrequent in colon and ovarian cancer and also in HCC (Wilson et al., 2000; Yuan et al., 2000; Yuan et al., 2002, manuscript in preparation) . Transfection of the DLC-1 cDNA into two HCC cell lines with homozygous deletions of the gene caused a strong inhibition of cell growth (Ng et al., 2000) .
To obtain further evidence that DLC-1 functions as a tumor suppressor gene, we expanded our investigations to include other types of cancer with frequent deletions in the chromosome 8p22 region. In this study, we examined alterations of DLC-1 in human breast, colon, and prostate tumor cell lines, and in primary breast tumors. We also tested the effect of the DLC-1 gene on cell growth and tumorigenicity, by transfecting with the DLC-1 cDNA three breast cancer cell lines with no expression of the endogenous gene. DLC-1 transfer into tumor cells caused both inhibitions of the cell growth and of the in vivo tumorigenicity, thus indicating that this gene acts as a tumor suppressor gene in breast cancer.
Results
The expression of DLC-1 mRNA was examined in 17 breast, 17 colon, and four prostate cancer cell lines. Six breast cancer cell lines (UACC-893, UACC-812, ZR-15B, SK-BR-3, MDA-MB-468, and MDA-MB-361) showed no expression of the gene, while in six other breast cancer lines (MDA-MB-330, BT-549, BT-483, ZR-75-1, BT-20, BT-474), DLC-1 mRNA appeared to be downregulated compared to the MCF-10F normal breast cell line (Figure 1a ). Among the colon cancer lines, four cell lines (LS 147T, SW1116, T84, SW403) showed no expression of the gene, while DLC-1 mRNA levels were decreased in another eight cell lines (HCT-15, DLD-1, HT-29, SW1417, SW480, SW948, LS 180, SW48) compared to the normal colon cell line CCD 33Co (Figure 1b) . In two out of four prostate cancer cell lines (LNCaP and PC-3M), no expression of DLC-1 was observed (Figure 1c) .
To determine whether the DLC-1 locus was recurrently deleted in breast cancer, we compared by Southern blot hybridization the copy number of the DLC-1 gene in 15 matched primary breast cancer/normal breast DNA samples. Six of the 15 tumor DNA samples displayed deletion of the DLC-1 gene. A representative Southern blot of BgllI-digested genomic DNA from two primary breast cancers that reveals deletion of the DLC-1 gene is shown (Figure 1d To test the effect of DLC-1 on colony formation, cells transfected with DLC-1 and control vector were cultured in G418 for 2 weeks and the colony number was counted on crystal-violet-stained dishes. A dramatic reduction (over 50%) in the number of G418-resistant colonies was observed in DLC-1 transfected compared to vector alone transfected cultures in both MDA-468 and MDA-MB-361 cells (Figure 3) .
To further assess the inhibitory effects of DLC-1, we tested the tumorigenicity of the 3 DLC-1-transfected breast tumor cell lines in Balb/c athymic nude mice. The G418-resistant MDA-486 and MDA-MB cells transfected with pLXSN/DLC-1, or the vector alone were harvested, assayed for viability by trypan-blue staining, counted and injected into nude mice. Animals that received MDA-468 DLC-1 or MDA-MB-361 DLC-1-transfected cells remained tumor-free for the length of the experiment of over 3 months. However, animals injected with MDA-486 or MDA-MB-361 cells transfected with the vector alone developed tumors during the first 3 weeks of the experiment, which continued to grow progressively (Table 1 ). Histopathological analysis of the tumors was consistent with mammary adenocarcinoma.The third line tested, UACC-893, although derived from an infiltrating ductal carcinoma, did not produce tumors.
In order to establish the copy number of the DLC-1 gene in the breast cancer cell lines used for in vivo tumorigenicity studies, chromosome metaphases and interphase nuclei from MDA-MB-468 and MDA-MB-361 cells were hybridized in situ with the DLC-1 genomic probe. Both MDA-MB-468 and MDA-MB-361 lines are aneuploid with 60-67 and 55-61 chromosomes per cell, respectively. FISH analysis showed one copy of DLC-1 in majority of MDA-MB-361 cells, and predominantly two copies of the gene in MDA-MB-468 cells. However, an additional copy above the average was detected only in MDA-MB-361 DLC-1-transfected cells, very likely resulting from duplication of the 
Discussion
In this study we have demonstrated that the DLC-1 gene is deleted in 40% of primary breast tumors and downregulated or not expressed in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines examined. Examining the effects of this gene on in vitro cell growth and in vivo tumorigenicity, we have also shown that the transfection of the DLC-1 cDNA into two breast carcinoma cell lines that lack DLC-1 expression caused a significant inhibition of cell growth in vitro and colony formation. MDA-MB-468 and MDA-MB-361 lines were isolated from patients with metastatic breast adenocarcinoma and exhibit high-level amplification of the ErbB-2 oncogene (Zimonjic et al., 2000) . Although they contain one or two copies of DLC-1, they do not express the gene because of promoter hypermethylation . Both cell lines formed tumors in nude mice, but introduction of the DLC-1 cDNA abolished their in vivo tumorigenicity.
An association of chromosome 8p loss and metastasis has earlier been demonstrated by CGH in human HCC (Qin et al., 1999) . Similarly, LOH at 8p21-22 in HCC, breast, and prostate carcinomas was associated with an invasive tumor phenotype and metastasis (Yaremko et al., 1998; Jenkins et al., 1998; Qin et al., 2001) . Interestingly, two isogenic breast cancer cell lines with diametrically opposite metastatic capabilities were derived from MDA-MB-435 cells. DLC-1 and two other tumor suppressor genes, DPC4 (Smad-4) and BARD1, were identified as downregulated in the nonmetastatic relative to the metastatic human breast cancer cell line (Euer et al., 2002) . By Affymetrix microarray gene expression analysis, DLC-1 was . This striking difference in DLC-1 expression relative to tumor phenotype raises the possibility that downregulation or loss of the DLC-1 gene is involved in the metastatic process. This assumption is compatible with the ability of the Rho family proteins to remodel the actin cytoskeleton, leading to tumor cell migration and invasion (Yoshioka et al., 1998) . Although the Rho branch of the small GTPase family was identified in human cancer more than 15 years ago, only in the past few years has evidence accumulated implicating Rho protein signaling in malignant transformation and metastasis (Boetter and van Aelst, 2002; Jaffe and Hall, 2002) . DLC-1 gene deregulation in cancer cells is one of several examples of the involvement of Rho GAP genes in human cancer development. Among the others are GRAF, a tumor suppressor gene, which is deleted or mutated in myelodysplastic syndromes, and the p190-A gene, which is located in a region of deletion and recombination in gliomas and astrocytomas (Borkhardt et al., 2000; Tikoo et al., 2000) .
Despite the large number of complex genomic changes in breast cancer, gain of 1q and loss of 8p and 13 are represented in over 90% of the cases (Tirkkonen et al., 1998) . Significantly, two genes coding for novel DLC-1-related proteins have been identified in the human cDNA and genomic DNA sequence databases, one mapping to chromosome 13q14 (GenBank AL049801) and another at chromosome Xq13 (KIAA0189 gene, Nagase et al., 1996; GenBank D80011) . It is possible that simultaneous deletion or inactivation of the DLC-1 gene on 8p and its isoform on 13q, both regions of recurrent loss of DNA copy number and LOH in both breast and several other cancers, may contribute in concert to tumor development and metastasis.
In summary, our current observations provide evidence that DLC-1 plays a role in cancer development by acting as a bona fide tumor suppressor gene that can inhibit the proliferation and tumorigenicity of cancer cells. Our preliminary indications are that DLC-1 expression has an inhibitory effect on in vitro cell growth and in vivo tumorigenicity not only in breast cancer cell lines but also in HCC-derived and prostate carcinoma-derived cell lines. In addition, we have isolated and characterized the mouse DLC-1 gene (Yuan et al., 1999; Durkin et al., 2002) and have constructed a targeting vector for generating mice with a null allele of the gene by homologous recombination. This step should shed additional light on the function and tumor suppressor status of the DLC-1 gene.
Materials and methods

Cell lines
Most of the breast and colon tumor cell lines as well as normal human breast and colon cells were purchased from the American Type Culture Collection. Three prostate carcinoma cell lines, LNCaP, SP3031 and PS-3M, were kindly provided by Dr Sen Pathak (The University of Texas, MD Anderson Cancer Center, Houston, TX, USA). Cells were cultured in DMEM/F12 or RPMI1640 media with 10% fetal bovine serum and antibiotics.
Northern blot analysis
Total RNA was extracted from cell lines using TRIzol reagent (Life Technologies, Inc., Grand Island, NY, USA). In all, 20 mg of total RNA of each sample was resolved on 1% agarose/MOPS/formaldehyde gels, transferred to a nylon membrane, and hybridized to a 32 P-labeled human DLC-1 full-length cDNA in QuikHyb buffer (Stratagene). The blot was washed twice at room temperature in 1.0 Â SSC/0.1% SDS for 30 min each, once in 0.1 Â SSC/0.1% SDS at 621C for 30 min, then exposed to a phosphorimager plate, and the image analyzed by ImageQuant ersion 3.3 software (Molecular Dynamics, Sunnyvale, CA, USA). After stripping, the blot was hybridized to GAPDH cDNA probe.
Southern blot analysis
Genomic DNAs extracted from human primary breast cancer tissue derived from patients in Iceland and peripheral blood of the same patient were digested with BglII, separated on 1% agarose gels, and blotted onto nylon membranes. The membrane was first hybridized to the 32 P-labeled L7-3 probe, a 500 bp genomic fragment of the DLC-1 gene originally isolated by representative difference analysis from a human primary HCC tissue (Yuan et al., 1998) , then stripped and rehybridized to a 32 P-labeled b-actin cDNA probe. Hybridization, washing, and detection were performed as described above for Northern blots.
Construction of DLC-1 cDNA expression vector, transfection, and assays for cell proliferation and colony formation The 3.3 kb full-length DLC-1 open reading frame starting from the ATG codon to the TGA stop codon (nt 348-3600 of GenBank AF035119) was amplified by PCR from human placental cDNA. The primers included BamHI linkers, and at the 5 0 end the forward primer incorporated the Flag antigen sequence, 5 0 GAC TAC AAG GAC GAC GAT GAC AAG 3 0 , to serve as a tag for expression of the protein. After digestion with BamHI, the PCR product was inserted into the BamHI site of the multiple cloning site of the pLXSN retrovirus expression vector (CLONTECH, Palo Alto, CA, USA). DNA sequencing and restriction enzyme digestion were used to confirm that the sequence and orientation of the construct were correct. To assay the effect of DLC-1 on cell growth, 2 Â 10 5 MDA-MB-468 and MDA-MB-361 cells were seeded in 25 cm flasks and transfected with 5 mg of either pLXSN-DLC-1 or pLXSN vector alone using cationic lipid reagents. The cells were trypsinized and counted at the designed time. To test for colony formation, MDA-MB-468 and MDA-MB-361 cells grown to 20% confluence in 100 mm tissue culture dishes were transfected with 5 mg of either pLXSN-DLC-1 or pLXSN as indicated above. After 48 h the transfection medium was replaced with medium containing 250 mg/ml G418 (Geneticin; Life Technologies, Inc). After 2 weeks the G418-resistant colonies were washed twice with PBS, stained with crystal violet, and counted.
Tumorigenicity assay
MDA-MB-468, UACC 893, and MDA-MB-301 cells stably transfected with pLXSN-DLC-1 or vector only that survived G418 selection were used for this assay. The cells were harvested before inoculation and resuspended in medium without serum and antibiotics. The cells were washed with medium twice, and 1 or 2 Â 10 6 cells were inoculated subcutaneously at the proximal dorsal midline of 4-weekold Balb/c athymic nude mice (NCI breeding facility). Tumor size was measured in two dimensions twice a week. For histopathologic examination, pieces of tumor tissue were fixed in 10% neutral buffered formalin, embedded in paraffin, cut, deparaffinized and stained with hematoxylin and eosin.
FISH A human BAC clone (RP11-465E23), which contains the sequence of the entire DLC-1 gene, was identified by a search of the GenBank High-Throughput Genomic Sequence database and purchased from Research Genetics. Biotinylated BAC DNA was hybridized on interphase nuclei from MDA-MB-468 and MDA-MB-361 transfected and control cells. Detection of the hybridization signal, digital image acquisition, and analysis were carried out as previously described (Zimonjic et al., 2000) .
